MM-206 |
| Katalog-Nr.GC44227 |
MM-206, ein STAT3-AktivitÄtsinhibitor, hemmt wirksam die STAT3-SH2-DomÄnen-Phosphopeptid-Wechselwirkung mit IC50 von 1,2 μM. MM-206 zeigt eine dosisabhÄngige Induktion der Apoptose in Zelllinien der akuten myeloischen LeukÄmie (AML).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1809581-87-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MM-206 is an inhibitor of STAT3 (IC50 = 1.16 µM in an SPR-based competitive assay). It inhibits STAT3 phosphorylation induced by granulocyte colony-stimulating factor (G-CSF) in HL-60, Kasumi-1, and MOLM-13 acute myeloid leukemia (AML) cells (IC50s = 0.8, 1.9, and 1.1 µM, respectively). MM-206 induces apoptosis more potently in AML cell lines and patient-derived primary AML tumor cells than in acute lymphoblastic leukemia cells, which do not have upregulated STAT3 activity. It also slows disease progression and improves survival in an AML mouse xenograft model when administered at a dose of 30 mg/kg per day.
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *